Wood D F, Docherty K, Ramsden D B, Sheppard M C
Department of Endocrinology, Queen Elizabeth Hospital, Edgbaston, Birmingham, U.K.
Mol Cell Endocrinol. 1987 Aug;52(3):257-61. doi: 10.1016/0303-7207(87)90052-9.
The effects of the dopamine agonist bromocriptine (BCR) have been compared with those of somatostatin (SS) on growth hormone (GH) synthesis and secretion by rat anterior pituitary cells in vitro. Both BCR and SS produced a dose-related reduction in GH release. Cytoplasmic GH mRNA levels were unchanged by BCR treatment and this finding was associated with an increase in total intracellular GH content. The reduction in GH release seen following SS treatment was accompanied by a fall in cytoplasmic GH mRNA levels and no significant change in intracellular GH content. These results suggest that the effects of BCR are predominantly on GH release mechanisms, whereas SS appears not only to regulate hormone release but also to regulate GH gene expression at a pre-translational level.
在体外实验中,比较了多巴胺激动剂溴隐亭(BCR)和生长抑素(SS)对大鼠垂体前叶细胞生长激素(GH)合成与分泌的影响。BCR和SS均使GH释放呈剂量依赖性减少。BCR处理后细胞质中GH mRNA水平未发生变化,这一结果与细胞内总GH含量增加相关。SS处理后GH释放减少的同时,细胞质中GH mRNA水平下降,而细胞内GH含量无显著变化。这些结果表明,BCR的作用主要在GH释放机制上,而SS似乎不仅调节激素释放,还在转录前水平调节GH基因表达。